Migraines, Insomnia, and Seizures Lecture Review

Classification and Pathophysiology of Headaches

• Headache Overview: Recognized as the most common neurologic symptom. Headaches may be classified as vascular, muscle-contraction, or a combination of both. Clinical presentation ranges from mild to severe discomfort.

• Red Flag Headache: A clinical designation for a headache that may indicate a serious underlying condition. Potential causes include hemorrhage, infection, intracranial tumors, or increased intracranial pressure (ICP).

• Thunderclap Headache: Characterized by a sudden, severe onset often described by patients as the "worst headache of my life." This is a classic diagnostic sign of a subarachnoid hemorrhage.

• Vascular Emergency Headache: Headaches associated with acute vascular crises such as a hypertensive crisis, stroke, or intracranial bleeding.

• Space-Occupying Headache: Pain resulting from mass effect or increased intracranial pressure. Common etiologies include brain tumors, brain abscesses, or cerebral swelling.

• Infectious Headache: Pain associated with systemic or localized infections such as meningitis or encephalitis. These are frequently accompanied by systemic symptoms like fever and physical signs like a stiff neck.

• Tension Headache: Described as a band-like pressure around the head. These are caused by muscle tension or stress and are typically mild to moderate in severity.

• Migraine Headache: A moderate to severe unilateral throbbing headache. It is typically associated with systemic and sensory symptoms, including nausea, vomiting, photophobia (sensitivity to light), and phonophobia (sensitivity to sound).

• Migraine Aura: Brief neurologic symptoms that manifest shortly before the onset of a migraine. Examples include visual flashes, specific smells, or sensory changes.

• Cluster Headache: A severe unilateral headache focused around the eye. It is accompanied by autonomic symptoms such as tearing (lacrimation), nasal congestion, ptosis (drooping eyelid), or miosis (pupillary constriction).

Migraine Management and Pharmacology

• Migraine Triggers: Various factors that can precipitate an attack, including stress, hormonal fluctuations, flashing lights, strong odors, specific food items, and disruptions in sleep patterns.

• Migraine Abortive Therapy: Pharmacological intervention initiated at the onset of a migraine attack with the goal of stopping or reducing the severity of existing symptoms.

• Migraine Preventive Therapy: Medications taken on a regular, scheduled basis to reduce the overall frequency and severity of future migraine attacks.

• Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Medications used in migraine treatment that inhibit cyclooxygenase (COX) enzymes. This action decreases prostaglandin production, thereby reducing inflammation and pain.

• Acetaminophen: A mild analgesic utilized for mild migraine treatment. It functions through central pain inhibition.

• Caffeine: Used as an adjunct in migraine therapy. It enhances the absorption of analgesics and induces cerebral vasoconstriction to improve headache relief.

• Triptans: A class of selective serotonin ($5\text{-HT}_{1B/1D}$) receptor agonists. They cause cranial vasoconstriction and are used for acute migraine treatment.

  • Sumatriptan: The prototype drug within the triptan class used for acute migraine attacks.

  • Triptan Contraindications: These drugs are contraindicated in patients with coronary artery disease (CAD), a history of stroke, uncontrolled hypertension, or peripheral vascular disease.

• Ergotamine: A migraine medication that causes prolonged cranial vasoconstriction and inhibits neurogenic inflammation.

  • Precautions: Contraindicated in patients with cardiovascular disease, uncontrolled hypertension (due to ischemia risk), and during pregnancy.

• Medication-Overuse Headache: Also known as rebound headaches, these are caused by the frequent or excessive use of analgesics or specific migraine medications.

• Serotonin Syndrome: A potentially life-threatening condition resulting from excessive serotonin activity. Risk increases when triptans are combined with Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs).

Insomnia and Sedative-Hypnotic Therapy

• Insomnia: Defined as the inability to fall asleep, stay asleep, or feel refreshed after a sleep period.

  • Acute Insomnia: Short-term sleep disturbance lasting from days to weeks.

  • Chronic Insomnia: Sleep disturbance lasting longer than one month.

• Non-restorative Sleep: Sleep that fails to provide adequate recovery. It is often driven by Central Nervous System (CNS) hyperarousal and disrupted sleep cycles.

• Sleep Hygiene: Behavioral interventions to improve sleep quality. Examples include avoiding caffeine before bedtime, maintaining a consistent sleep routine, and reducing nighttime stimulation.

• Sedative-Hypnotics: A category of drugs that depress the CNS to promote sleep.

• Pharmacological Principles:

  • Tolerance: A reduction in drug effectiveness over time, necessitating higher doses to achieve the same therapeutic effect.

  • Dependence: A physiologic or psychological need for a substance that can result in withdrawal symptoms upon discontinuation.

• Gamma-Aminobutyric Acid (GABA): The primary inhibitory neurotransmitter within the Central Nervous System.

• Benzodiazepines: Drugs that enhance GABA activity at the $\text{GABA-A}$ receptors, leading to sedation and decreased neuronal excitability.

  • Mechanism of Action: Increases GABA activity, which triggers the opening of chloride channels and leads to neuronal hyperpolarization.

  • Hyperpolarization: An increase in the negative charge within a neuron, which reduces the probability of neuronal firing.

  • Temazepam: A benzodiazepine commonly used for the short-term management of insomnia.

  • Triazolam: Another benzodiazepine used short-term for insomnia treatment.

  • Flumazenil: The specific antidote used to reverse benzodiazepine toxicity.

  • Black Box Warning: Dangerous interaction when combining benzodiazepines with opioids or alcohol, which can lead to severe respiratory depression and death.

• Zolpidem: A non-benzodiazepine sedative-hypnotic for short-term insomnia treatment.

  • Serious Risks: Potential for complex sleep behaviors (e.g., sleep-walking or sleep-driving) and the worsening of clinical depression.

• Ramelteon: A melatonin receptor agonist used for sleep-initiation insomnia.

  • Mechanism: Stimulates $MT_1$ and $MT_2$ receptors to regulate the circadian rhythm and promote sleep.

Seizure Disorders and Epilepsy

• Seizure: A transient occurrence of abnormal electrical activity in the brain that results in changes in movement, behavior, or consciousness.

• Epilepsy: A chronic neurologic disorder defined by recurrent, unprovoked seizures.

• Phases of a Seizure:

  • Prodromal Phase: An early warning phase occurring hours or days before a seizure, often characterized by behavioral or mood changes.

  • Aura: A brief sensory warning immediately preceding a seizure (e.g., unusual smells or visual disturbances).

  • Ictal Phase: The period of active seizure activity, marked by abnormal neurologic or motor behavior.

  • Postictal Phase: The recovery period following a seizure. Patients may experience fatigue, headache, and confusion.

• Seizure Types:

  • Focal Seizure: Originates in one localized area of the brain.

  • Tonic-Clonic Seizure: A generalized seizure involving loss of consciousness and rhythmic muscle contractions.

  • Absence Seizure: A brief seizure marked by a sudden staring spell and loss of awareness; notably lacks a postictal confusion phase.

  • Atonic Seizure: Characterized by a sudden loss of muscle tone, leading to a "drop attack."

  • Status Epilepticus: A medical emergency defined by a seizure lasting longer than $5\,\text{minutes}$ or repeated seizures where the patient does not recover consciousness between episodes.

Antiepileptic Drug (AED) Pharmacotherapy

• Antiepileptic Drugs (AEDs) General Principles: Medications designed to control seizures by reducing neuronal hyperexcitability.

  • Withdrawal Risk: Abruptly stopping AEDs can trigger status epilepticus or rebound seizures.

  • Status Epilepticus Treatment: Initial treatment involves benzodiazepines, followed by the administration of intravenous (IV) antiepileptic drugs.

  • Patient Education: Patients should avoid alcohol, maintain strict consistency in timing, and never discontinue medication without a provider-led taper.

• Traditional AEDs: Older medications often associated with more drug-drug interactions and side effects.

  • Phenytoin: Blocks sodium channels to stabilize neuronal membranes.

    • Therapeutic Level: $10-20\,\text{mcg/mL}$.

    • Toxicity: Ataxia is a classic early sign of toxic levels.

    • Purple Glove Syndrome: A severe tissue injury resulting from the infiltration of IV phenytoin.

  • Carbamazepine: Used for seizures, bipolar disorder, and trigeminal neuralgia. Requires monitoring of the Complete Blood Count (CBC) due to risks of anemia, leukopenia, and thrombocytopenia.

  • Valproic acid: Increases GABA levels to decrease excitability. Carries a major risk of hepatotoxicity, requiring regular liver function tests (LFTs).

• Newer AEDs: Generally offer fewer interactions and improved side-effect profiles.

  • Levetiracetam: Features fewer drug interactions and is primarily eliminated via the renal system.

  • Gabapentin: Modulates calcium channels to reduce the release of excitatory neurotransmitters.

• Diagnostic Tools: EEG (Electroencephalogram) is used to record the electrical activity of the brain via scalp electrodes to support the diagnosis of seizures.